[et_pb_section fb_built=\u201d1\u2033 _builder_version=\u201d4.16\u2033 kilitli=\u201doff\u201d global_colors_info=\u201d{}\u201d][et_pb_row _builder_version=\u201d4.16\u2033 arka plan_size=\u201dinitial\u201d arka plan_position=\u201dtop_left\u201d arka plan_repeat=\u201dtekrar\u201d global_colors_info=\u201d{ }\u201d][et_pb_column type=\u201d4_4\u2033 _builder_version=\u201d4.16\u2033custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201dcustom_padding__hover=\u201d|||\u201d][et_pb_text _builder_version=\u201d4.23.1\u2033header_2_font_size=\u201d24px\u201dheader_2_line_height=\u201d1.4em\u201dbackground_size=\u201dinitial\u201dbackground_position=\u201dtop_left\u201dbackground_repeat=\u201drepeat\u201dcustom_padding =\u201d25px||||false|false\u201d global_colors_info=\u201d{}\u201d]Erken a\u011f\u0131z kanseri tespit \u00e7\u00f6z\u00fcmlerinde \u00f6nc\u00fc olarak Vigilant Biosciences\u00ae, tedavinin ba\u015flat\u0131lmas\u0131n\u0131 h\u0131zland\u0131rmak ve hastay\u0131 iyile\u015ftirmek i\u00e7in klinisyenlerin A\u015fama I ve II'de a\u011f\u0131z kanserini te\u015fhis etmesine yard\u0131mc\u0131 olmaya \u00e7al\u0131\u015fmaktad\u0131r. sonu\u00e7lar. Ekibimiz, a\u011f\u0131z kanseri tespitinde devrim yaratan ve sonu\u00e7ta hayat kurtaran \u00e7\u0131\u011f\u0131r a\u00e7an teknolojiler geli\u015ftirmek i\u00e7in onlarca y\u0131ll\u0131k uzman klinik uzmanl\u0131\u011f\u0131ndan ve sa\u011fl\u0131k hizmeti liderli\u011finden yararlan\u0131yor.[\/et_pb_text][et_pb_text _builder_version=\u201d4.23.1\u2033 head_2_font_size=\u201d24px\u201d head_2_line_height=\u201d1.4em \u201d arka plan_size=\u201dinitial\u201d arka plan_pozisyon=\u201dtop_left\u201d arka plan_repeat=\u201dtekrar\u201d \u00f6zel_padding=\u201d25px||||false|false\u201d hover_enabled=\u201d0\u2033 global_colors_info=\u201d{}\u201d sticky_enabled=\u201d0\u2033]<\/p>\n
A\u011f\u0131z kanseri halk sa\u011fl\u0131\u011f\u0131 a\u00e7\u0131s\u0131ndan \u00f6nemli bir tehdit olu\u015fturmaktad\u0131r. D\u00fcnya \u00e7ap\u0131nda her y\u0131l 744.000'den fazla vakayla1<\/sup> ve 50% be\u015f y\u0131ll\u0131k hayatta kalma oran\u0131n\u0131n alt\u0131nda2<\/sup>A\u011f\u0131z kanseri sonu\u00e7lar\u0131 son derece k\u00f6t\u00fc; ancak proaktif tarama ve erken te\u015fhisle iyile\u015ftirilebilir. Yayg\u0131n "bekle ve izle" uygulamas\u0131na g\u00f6re, a\u011f\u0131z lezyonlar\u0131na te\u015fhis konulamad\u0131\u011f\u0131nda hastalar s\u0131kl\u0131kla ge\u00e7 evre a\u011f\u0131z kanseri tan\u0131s\u0131yla kar\u015f\u0131 kar\u015f\u0131ya kal\u0131r. Asl\u0131nda a\u011f\u0131z kanserlerinin \u00fc\u00e7te ikisinden fazlas\u0131n\u0131n Evre III ve IV'te te\u015fhis edildi\u011fi tahmin edilmektedir.3<\/sup><\/p>\n \u00c7o\u011fu i\u00e7in hayatta kalmak, fiziksel i\u015flevi yeniden kazanmak ve a\u011f\u0131z sa\u011fl\u0131\u011f\u0131n\u0131 korumak i\u00e7in kapsaml\u0131 rekonstr\u00fcktif cerrahi, protezler, kemoterapi, radyasyon ve y\u0131llarca s\u00fcren rehabilitasyon tedavisi gerektirir. Hastalara A\u015fama I ve II'de te\u015fhis konulursa, yaln\u0131zca 80-90% oldu\u011fu tahmin edilen hayatta kalma \u015fanslar\u0131 daha y\u00fcksek olmakla kalmaz, ayn\u0131 zamanda b\u00fcy\u00fck ameliyatlardan, uzun iyile\u015fme s\u00fcrelerinden ve h\u0131zla artan kanser bak\u0131m\u0131 maliyetlerinden de ka\u00e7\u0131nabilirler. [\/et_pb_text][et_pb_text admin_label=\u201dGeleneksel Tarama Y\u00f6ntemlerinin Yetersiz Kald\u0131\u011f\u0131 Yer\u201d _builder_version=\u201d4.23.1\u2033header_2_font_size=\u201d24px\u201dheader_2_line_height=\u201d1.4em\u201dbackground_size=\u201dinitial\u201dbackground_position=\u201dtop_left\u201dbackground_repeat=\u201drepeat\u201dcustom_padding =\u201d25px||||false|false\u201d global_colors_info=\u201d{}\u201d]<\/p>\n Tarihsel olarak g\u00f6rsel muayene ve palpasyon gibi standart a\u011f\u0131z kanseri tarama y\u00f6ntemleri \u015f\u00fcpheli lezyonlar\u0131n belirlenmesinde merkezi bir rol oynam\u0131\u015ft\u0131r. Ancak bu y\u00f6ntemler \u00e7o\u011fu zaman erken evre belirti ve semptomlarla bile malignitelerin \u00f6n tan\u0131s\u0131n\u0131n konulmas\u0131nda yetersiz kalmaktad\u0131r. G\u00f6rsel incelemeler erken ve ince de\u011fi\u015fiklikleri kolayca g\u00f6zden ka\u00e7\u0131rabilirken, palpasyon genellikle mukozal y\u00fczeyin alt\u0131ndaki anormallikleri tespit etmekte ba\u015far\u0131s\u0131z olur. Tespit metodolojilerindeki do\u011fal \u00f6znellik, te\u015fhisin gecikmesine ve \u00f6nemli \u00f6l\u00e7\u00fcde daha k\u00f6t\u00fc sonu\u00e7lara neden olur.[\/et_pb_text][et_pb_text admin_label=\u201dBeVigilant\u2122 OraFusion\u2122 Sistemine Giri\u015f\u201d _builder_version=\u201d4.23.1\u2033 head_2_font_size=\u201d24px\u201d head_2_line_height=\u201d1.4em\u201d arka plan_size=\u201dinitial\u201d arka plan_pozisyon=\u201dtop_left\u201d arka plan_repeat=\u201dtekrar\u201d \u00f6zel_padding=\u201d25px||||false|false\u201d global_colors_info=\u201d{}\u201d]<\/p>\n Y\u0131llar s\u00fcren test ve geli\u015ftirmelerden sonra Vigilant Biosciences\u00ae, BeVigilant\u2122 OraFusion\u2122 Sistemi ile a\u011f\u0131z kanseri bak\u0131m\u0131nda ileriye do\u011fru b\u00fcy\u00fck bir ad\u0131m att\u0131. FDA taraf\u0131ndan belirlenen \u00e7\u0131\u011f\u0131r a\u00e7\u0131c\u0131 bir cihaz olan BeVigilant\u2122 OraFusion\u2122 Sistemi, hassas ve g\u00fcvenilir bir hastaba\u015f\u0131 risk de\u011ferlendirme arac\u0131 olarak hizmet ederek klinisyenlere, benzeri g\u00f6r\u00fclmemi\u015f bir do\u011fruluk ve g\u00fcvenle a\u011f\u0131z kanseri tespitini h\u0131zland\u0131rmak i\u00e7in ihtiya\u00e7 duyduklar\u0131 kritik bilgileri sa\u011flar.<\/p>\n BeVigilant\u2122 OraFusion\u2122 Sistemi, a\u011f\u0131z kanseri taramas\u0131n\u0131n \u00e7ehresini de\u011fi\u015ftirmek i\u00e7in en son teknolojiyi ve klinik titizli\u011fi birle\u015ftirir:[\/et_pb_text][et_pb_text admin_label=\u201dBeVigilant\u2122 OraFusion\u2122 Sistemiyle Tan\u0131\u015f\u0131n\u201d _builder_version=\u201d4.23.1\u2033 head_2_font_size= \u201d24px\u201d ba\u015fl\u0131k_2_line_height=\u201d1.4em\u201d arka plan_size=\u201dinitial\u201d arka plan_pozisyon=\u201dtop_left\u201d arka plan_repeat=\u201dtekrar\u201d \u00f6zel_margin=\u201d||||yanl\u0131\u015f|false\u201d \u00f6zel_padding=\u201d5px||||false|true\u201d global_colors_info=\u201d {}"]<\/p>\n [\/et_pb_text][et_pb_text admin_label=\u201dDaha fazla bilgi edinin\u201d _builder_version=\u201d4.23.1\u2033header_2_font_size=\u201d24px\u201dheader_2_line_height=\u201d1.4em\u201dbackground_size=\u201dinitial\u201dbackground_position=\u201dtop_left\u201dbackground_repeat=\u201drepeat\u201dcustom_padding=\u201d|| ||yanl\u0131\u015f|yanl\u0131\u015f\u201d global_colors_info=\u201d{}\u201d]<\/p>\n BeVigilant\u2122 OraFusion\u2122 Sisteminin, \u00f6n saflardaki klinisyenlerin saptamay\u0131 d\u00f6n\u00fc\u015ft\u00fcrmesine, sonu\u00e7lar\u0131 iyile\u015ftirmesine ve hayat kurtarmas\u0131na yard\u0131mc\u0131 olmak i\u00e7in \u00e7ok ihtiya\u00e7 duyulan verileri nas\u0131l sa\u011flad\u0131\u011f\u0131 hakk\u0131nda daha fazla bilgi edinin.<\/a><\/p>\n [\/et_pb_text][et_pb_text admin_label=\u201dSources\u201d _builder_version=\u201d4.22.2\u2033 text_font_size=\u201d14px\u201dheader_2_font_size=\u201d24px\u201dheader_2_line_height=\u201d1.4em\u201dbackground_size=\u201dinitial\u201dbackground_position=\u201dtop_left\u201dbackground_repeat=\u201drepeat\u201d global_colors_info =\u201d{}\u201d]Kaynaklar<\/strong><\/p>\n 1. D\u00fcnya Kanser Ara\u015ft\u0131rma Fonu Uluslararas\u0131. (2022, 14 Nisan). A\u011f\u0131z ve a\u011f\u0131z kanseri istatistikleri. WCRF Uluslararas\u0131. https:\/\/www.wcrf.org\/cancer-trends\/mouth-and-oral-cancer-statistics\/<\/a> Erken a\u011f\u0131z kanseri tespit \u00e7\u00f6z\u00fcmlerinde \u00f6nc\u00fc olan Vigilant Biosciences\u00ae, tedavinin ba\u015flat\u0131lmas\u0131n\u0131 h\u0131zland\u0131rmak ve hasta sonu\u00e7lar\u0131n\u0131 iyile\u015ftirmek i\u00e7in klinisyenlerin A\u015fama I ve II'de a\u011f\u0131z kanserini te\u015fhis etmesine yard\u0131mc\u0131 olmaya \u00e7al\u0131\u015fmaktad\u0131r. Ekibimiz, a\u011f\u0131z kanseri tespitinde devrim yaratan ve sonu\u00e7ta hayat kurtaran \u00e7\u0131\u011f\u0131r a\u00e7an teknolojiler geli\u015ftirmek i\u00e7in onlarca y\u0131ll\u0131k uzmanla\u015fm\u0131\u015f klinik uzmanl\u0131ktan ve sa\u011fl\u0131k hizmeti liderli\u011finden yararlan\u0131yor.Neden [\u2026]<\/p>","protected":false},"author":3,"featured_media":545,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-528","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"\nGeleneksel Tarama Y\u00f6ntemlerinin Yetersiz Kald\u0131\u011f\u0131 Yer<\/h2>\n
BeVigilant\u2122 OraFusion\u2122 Sistemiyle Tan\u0131\u015f\u0131n<\/h2>\n
\n
\n2. Gonz\u00e1lez-Moles, M.\u00c1., Aguilar-Ruiz, M. ve Ramos-Garc\u00eda, P. (2022). A\u011f\u0131z Kanserinin Erken Tan\u0131s\u0131ndaki Zorluklar, Kan\u0131t Eksiklikleri ve \u0130yile\u015ftirme Stratejileri: Sistematik \u0130ncelemelerin Kapsaml\u0131 Bir \u0130ncelemesi. Kanserler 14(19), 4967.
\n3. A\u011f\u0131z ve orofaringeal kanser \u2013 istatistikler. Kanser.Net. (2023, 9 May\u0131s). https:\/\/www.cancer.net\/cancer-types\/oral-and-oropharyngeal-cancer\/statistics<\/a>
\n4. Landis, G., Mardy, Z., Donovan, M., Nebrigic, D. (2022). Di\u015f Hekimli\u011fi Uygulamalar\u0131nda \u015e\u00fcpheli Oral Lezyonlar Risk De\u011ferlendirmesi i\u00e7in Yeni \u00c7\u0131\u011f\u0131r A\u00e7an OraFusion\u2122 Sistemi [Beyaz Kitap]. Vigilant Biosciences\u00ae.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":"